Actively Recruiting
Prospective Study of Adaptive Radiation Boost for Prostate and Bladder Cancers (SMART-B01)
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-01-07
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating if adaptive radiation boost can effectively treat genitourinary cancers, specifically prostate cancer patients with local relapse after prostate removal and bladder cancer patients undergoing bladder-conserving treatment. The study aims to determine whether adaptive boost reduces toxic side effects while maintaining or improving treatment effectiveness. This trial is sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Participants will receive adaptive radiation therapy using a 1.5-Tesla MR-Linac machine. Prostate cancer patients post-prostatectomy will receive specific radiation doses targeting the prostate bed and boost areas, while bladder cancer patients will receive targeted doses to the bladder tumor and surrounding tissues. Treatment visits occur once every two weeks during radiation therapy. Throughout the study, participants will attend clinic visits every two weeks during treatment and every three months afterward. They will complete regular quality-of-life questionnaires focusing on genitourinary, gastrointestinal, and sexual health. The study will monitor acute urinary and gastrointestinal toxicities three months after treatment and track long-term outcomes such as disease control, survival, late toxicities, and quality of life for up to two years.
CONDITIONS
Brief Title
Adaptive Radiotherapy for Genitourinary Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors suitable for adaptive radiotherapy
- Age 18 years or older
- ECOG performance status score 0-2
- No prior radiotherapy in the current radiation field
- No contraindications for MRI scanning
- No contraindications for radiotherapy
You will not qualify if you...
- Patients with contraindications to radiotherapy
- Patients unable to tolerate MRI or with contraindications to MRI scanning
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 5 to 7 weeks depending on cancer type and dosing schedule
Participants receive adaptive radiotherapy with radiation boosts tailored for prostate or bladder cancer.
Daily visits for radiation treatment sessions up to 33 sessions
Duration - Up to 2 years post-treatment
Participants are monitored for acute toxicities, quality of life, local control, disease-free survival, and late toxicities.
Visits at 1 month post-treatment, then every 3 months until 2 years
Trial Site Locations
Total: 1 location
1
Cancer Hospital, National Cancer Center, CAMS & PUMC
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
N
Ning-Ning Lu, M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here